Herpes Zoster
Conditions
Keywords
Vaccine, Safety, Herpes Zoster, Immunogenicity, Stem cell transplantation
Brief summary
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
Detailed description
The Protocol Posting has been updated following Protocol amendment 2, Sep 2009. The sections impacted are: eligibility criteria.
Interventions
BIOLOGICALHerpes Zoster Vaccine 1437173A
Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
BIOLOGICALPlacebo vaccine (saline)
1 or 3 doses of Placebo (saline) injected intramuscularly.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol; * Male and female subjects at least 18 years old at the time of vaccination; * Serological evidence of prior VZV infection for all subjects born in 1980 or later and for subjects born outside the US before 1980 in a tropical or sub-tropical region. No testing for serological evidence of prior VZV infection is required for US subjects born before 1980; * Has undergone autologous HCT within the past 50-70 days for treatment of Hodgkin lymphoma, non-Hodgkin lymphoma (T or B cell), myeloma or acute myeloid leukemia, and there are no plans for additional HCTs * Written informed consent obtained from the subject; * If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
Exclusion criteria
* Use of any investigational non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period; * Administration or planned administration of a vaccine that is not part of the study protocol since transplantation. However licensed non-replicating vaccines (i.e. inactivated and subunit vaccines, including inactivated and subunit influenza vaccines, with or without adjuvant) may be administered up to 8 days prior to dose 1; * Administration of immunoglobulins since transplantation; * Previous vaccination against varicella or HZ; * History of HZ within the previous 12 months; * Known exposure to VZV since transplantation; * Evidence of active infection at the time of enrollment including a temperature of ≥ 37.5° C or any serious HCT-related complication; * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine; * Hypersensitivity or intolerance to acyclovir or valacyclovir; * Pregnant or lactating female.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-gE Mean Antibody Concentrations | At Month 4 | Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL). |
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | During the 7-days (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited general symptoms were fatigue, gastrointestinal symptoms \[including nausea, vomiting, diarrhoea and abdominal pain\], temperature \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | During the 30-day (Days 0-29) post-vaccination period | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. |
| Number of Subjects With Serious Adverse Events (SAEs) | Any time during the study up to Day 29 after the last vaccination | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | Within the 30-day (Days 0-29) post last vaccination period | Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases. |
| Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | At Month 0 | Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC). |
| Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 4 | The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS). |
| Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations | At Month 4 | Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL). |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | During the 7-days (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Months 0, 1, 2, 3 and 15 | The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS). |
| Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Months 0, 1, 2, 3, 4 and 15 | Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL). |
| VZV-specific Mean Antibody Concentrations | At Months 0, 1, 2, 3, 4 and 15 | Concentrations are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL). |
| Anti-gE Geometric Mean Antibody Concentrations | At Months 0, 1, 2, 3 and 15 | Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL). |
| Anti-gE Mean Antibody Concentrations | At Months 0, 1, 2, 3 and 15 | Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL). |
| Number of Subjects With Confirmed Herpes Zoster (HZ) Cases | During the entire study period (from Day 0 to Month 15) | A suspected case of HZ could be confirmed by PCR and/or by clinical review of the GSK physician responsible for the study. Rash lesion samples collected from subjects clinically diagnosed as having a suspected case of HZ were tested by by polymerase chain reaction (PCR) using standardized and validated procedures for the laboratory diagnosis of HZ. If the PCR specimen was inadequate or was missing, suspected HZ cases were to be classified as 'a confirmed case of HZ' or 'not a case of HZ' based on the determination by the GSK responsible physician of the study. |
| Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Months 0, 1, 2, 3, 4 and 15 | The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS). |
Countries
United States
Participant flow
Recruitment details
Serological evidence of prior Varicella-Zoster Virus infection for those born in 1980 or later and for those born outside the US before 1980 in a tropical or sub-tropical region was required. All subjects were to have undergone autologous hematopoietic stem cell transplantation (HCT) within the past 50-70 days; and had no additional HCTs planned.
Pre-assignment details
Out of the 121 subjects enrolled into this study, 1 subject was eliminated due to not receiving study vaccination and hence only 120 subjects started.
Participants by arm
| Arm | Count |
|---|---|
| GSK 1437173A F1 Group Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule. | 30 |
| GSK 1437173A F2 Group Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule. | 29 |
| Placebo-GSK 1437173A F1 Group Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule. | 31 |
| Placebo Group Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule. | 30 |
| Total | 120 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 1 | 0 | 3 |
| Overall Study | Migrated/moved from study area | 0 | 0 | 1 | 0 |
| Overall Study | Other | 0 | 0 | 1 | 0 |
| Overall Study | Serious Adverse Event | 2 | 0 | 2 | 1 |
| Overall Study | Transplant failed/malignancy recurrence | 0 | 1 | 2 | 3 |
| Overall Study | Withdrawal by Subject | 0 | 3 | 2 | 0 |
Baseline characteristics
| Characteristic | GSK 1437173A F1 Group | GSK 1437173A F2 Group | Placebo-GSK 1437173A F1 Group | Placebo Group | Total |
|---|---|---|---|---|---|
| Age, Continuous | 53.1 Years STANDARD_DEVIATION 12.2 | 56.0 Years STANDARD_DEVIATION 11.4 | 57.8 Years STANDARD_DEVIATION 6.8 | 57.3 Years STANDARD_DEVIATION 8.6 | 56.1 Years STANDARD_DEVIATION 10 |
| Race/Ethnicity, Customized Race/Ethnicity African Heritage/African American | 2 Participants | 2 Participants | 1 Participants | 1 Participants | 6 Participants |
| Race/Ethnicity, Customized Race/Ethnicity American Indian or Alaskan Native | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Asian-Central/South Asian Heritage | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Asian-East Asian Heritage | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Asian-Japanese Heritage | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Race/Ethnicity Other | 2 Participants | 2 Participants | 0 Participants | 4 Participants | 8 Participants |
| Race/Ethnicity, Customized Race/Ethnicity White-Arabic/North African Heritage | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Race/Ethnicity White-Caucasian/European Heritage | 24 Participants | 24 Participants | 30 Participants | 22 Participants | 100 Participants |
| Sex: Female, Male Female | 12 Participants | 9 Participants | 10 Participants | 11 Participants | 42 Participants |
| Sex: Female, Male Male | 18 Participants | 20 Participants | 21 Participants | 19 Participants | 78 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 30 | 1 / 29 | 2 / 31 | 3 / 30 |
| other Total, other adverse events | 29 / 30 | 27 / 29 | 29 / 31 | 21 / 30 |
| serious Total, serious adverse events | 6 / 30 | 9 / 29 | 10 / 31 | 8 / 30 |
Outcome results
Primary
Anti-gE Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Month 4
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GSK 1437173A F1 Group | Anti-gE Mean Antibody Concentrations | 131471.10 mIU/mL | Standard Deviation 169644.69 |
| GSK 1437173A F2 Group | Anti-gE Mean Antibody Concentrations | 102106.14 mIU/mL | Standard Deviation 116349.94 |
| GSK 1437173A 2D Group | Anti-gE Mean Antibody Concentrations | 63768.06 mIU/mL | Standard Deviation 100839.95 |
| Placebo 1D Group | Anti-gE Mean Antibody Concentrations | 840.46 mIU/mL | Standard Deviation 1119.44 |
Primary
Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Month 4
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| GSK 1437173A F1 Group | Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations | 29192.9 mIU/mL |
| GSK 1437173A F2 Group | Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations | 22503.0 mIU/mL |
| GSK 1437173A 2D Group | Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations | 11064.6 mIU/mL |
| Placebo 1D Group | Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations | 406.0 mIU/mL |
Comparison: The null hypothesis was H0: GSK 1437173A 1 Group/Placebo Group \< 1.p-value: <0.000176.16% CI: [33.12, 167.17]Dunnett for multiple comparisons
Comparison: The null hypothesis was H0: Placebo-GSK 1437173A 1 Group/Placebo Group \< 1.p-value: <0.000176.16% CI: [20.2, 88.13]Dunnett for multiple comparisons
Primary
Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
Time frame: At Month 4
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GSK 1437173A F1 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | 11963.56 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 11655.09 |
| GSK 1437173A F2 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | 8114.83 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 9957.55 |
| GSK 1437173A 2D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | 6974.97 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 10437.53 |
| Placebo 1D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | 96.15 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 108.08 |
Comparison: The null hypothesis was H0: GSK 1437173A F1 Group/Placebo Group below (\<) 1.p-value: <0.000176.16% CI: [20.65, 50.54]Dunnett for multiple comparisons
Comparison: The null hypothesis was H0: Placebo-GSK 1437173A F1 Group/Placebo Group \< 2.p-value: <0.000176.16% CI: [6.07, 14.9]Dunnett for multiple comparisons
Primary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-days (Days 0-6) post-vaccination period following each dose and across doses
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented, who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 3 | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across Doses | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across Doses | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across Doses | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across Doses | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across Doses | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 19 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across Doses | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across Doses | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 19 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 6 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across Doses | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across Doses | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across Doses | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 3 | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across Doses | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across Doses | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across Doses | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across Doses | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across Doses | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across Doses | 24 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across Doses | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across Doses | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 4 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 1 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across Doses | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across Doses | 4 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across Doses | 1 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 3 | 4 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across Doses | 7 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 3 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 3 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across Doses | 1 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 3 | 0 Participants |
Primary
Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Any AEs | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Grade 3 AEs | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Any AEs | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Grade 3 AEs | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Any AEs | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Grade 3 AEs | 2 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Grade 3 AEs | 1 Participants |
| Placebo 1D Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Any AEs | 16 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Any AEs | 21 Participants |
| Placebo Group | Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs) | Grade 3 AEs | 4 Participants |
Primary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms \[including nausea, vomiting, diarrhoea and abdominal pain\], temperature \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-days (Days 0-6) post-vaccination period following each dose and across doses
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented, who had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 12 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 14 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across Doses | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 3 | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across Doses | 19 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 1 | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 1 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 1 | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across Doses | 12 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across Doses | 10 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across Doses | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across Doses | 18 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 3 | 12 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 3 | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 5 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 3 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across Doses | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 3 | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Across Doses | 10 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 3 | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 15 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Across Doses | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 3 | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 10 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 12 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Across Doses | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 3 | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 13 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 2 | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across Doses | 13 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 14 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 2 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 2 | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across Doses | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 13 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 10 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across Doses | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across Doses | 11 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across Doses | 21 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 18 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 1 | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 10 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 11 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across Doses | 11 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Across Doses | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Across Doses | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Across Doses | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across Doses | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across Doses | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across Doses | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across Doses | 18 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across Doses | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across Doses | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across Doses | 8 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across Doses | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across Doses | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 1 | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 1 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 12 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 9 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 8 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 2 | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 2 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 2 | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 13 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 11 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 8 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 3 | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 3 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 3 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 3 | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 3 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 3 | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 3 | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across Doses | 18 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across Doses | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 12 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 2 | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 19 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Across Doses | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 1 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 13 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across Doses | 16 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across Doses | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 1 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across Doses | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 1 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across Doses | 14 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 10 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across Doses | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 16 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across Doses | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across Doses | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across Doses | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Across Doses | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across Doses | 20 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 10 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across Doses | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across Doses | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 2 | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across Doses | 9 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 12 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 2 | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Across Doses | 1 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 7 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 6 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 7 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across Doses | 2 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 2 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 5 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across Doses | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 15 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across Doses | 7 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Across Doses | 3 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across Doses | 15 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 6 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across Doses | 5 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Across Doses | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Across Doses | 9 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across Doses | 6 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across Doses | 7 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across Doses | 2 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 1 | 9 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across Doses | 6 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across Doses | 1 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 1 | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 1 | 3 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across Doses | 9 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across Doses | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 2 Participants |
| Placebo 1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 9 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Across Doses | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 3 | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 2 | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Across Doses | 4 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 3 | 3 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 3 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Across Doses | 8 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 3 | 8 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across Doses | 6 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 3 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across Doses | 5 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 3 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across Doses | 4 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across Doses | 5 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across Doses | 10 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 8 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 3 | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Across Doses | 5 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across Doses | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastr. sympt., Dose 1 | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 1 | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 3 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 3 | 3 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 7 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 1 | 3 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 1 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Across Doses | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Dose 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 3 | 4 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across Doses | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 3 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 2 | 5 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 3 | 4 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastr. sympt., Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia, Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastr. sympt., Across Doses | 0 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 1 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia, Dose 3 | 5 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia, Dose 2 | 3 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 2 Participants |
| Placebo Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 1 Participants |
Primary
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders
Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
Time frame: Within the 30-day (Days 0-29) post last vaccination period
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
Primary
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders
Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.
Time frame: During the entire study period (from Day 0 to Month 15)
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
| Placebo 1D Group | Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders | 0 Participants |
Primary
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 4
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 17 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 12 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 18 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 11 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 22 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 21 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 19 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 21 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 16 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 21 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 19 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 11 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 14 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 12 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 21 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 16 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 10 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 19 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 11 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 13 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 20 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 19 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 25 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 14 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 17 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 10 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 9 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 18 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 20 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 23 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 9 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 17 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 23 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 24 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 20 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 9 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 23 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 16 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 19 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 21 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 20 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 20 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 22 Participants |
Primary
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 0
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 5 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 19 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 29 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 11 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 30 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 21 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 5 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 30 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 22 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 29 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 29 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 29 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 27 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 28 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 14 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 6 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 28 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 21 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 28 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 8 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 20 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 25 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 31 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 9 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 30 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 30 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 20 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 31 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 29 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 9 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 19 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 29 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 7 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 10 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 29 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 19 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 28 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 23 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 23 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 21 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 24 Participants |
Primary
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 1
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 30 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 11 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 5 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 22 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 29 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 5 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 29 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 11 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 19 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 30 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 13 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 22 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 19 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 17 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 6 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 27 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 20 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 28 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 6 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 28 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 18 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 10 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 9 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 19 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 9 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 27 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 29 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 13 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 28 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 17 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 10 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 19 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 19 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 25 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 28 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 16 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 13 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 21 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 9 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 29 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 30 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 28 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 24 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 7 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 7 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 23 Participants |
Primary
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 2
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 29 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 24 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 20 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 21 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 22 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 10 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 19 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 20 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 17 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 12 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 6 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 13 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 18 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 14 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 14 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 9 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 19 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 10 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 28 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 18 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 7 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 21 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 9 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 25 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 28 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 20 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 9 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 29 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 25 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 28 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 8 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 19 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 7 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 20 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 21 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 21 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 21 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 24 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 6 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 22 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 24 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 6 Participants |
Primary
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).
Time frame: At Month 3
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 21 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 15 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 10 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 20 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 7 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 26 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 8 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 16 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 25 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 27 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 9 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 28 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 4 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 16 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 20 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 20 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 6 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 23 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 11 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 14 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 13 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 12 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 3 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 1 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 2 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F1 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 27 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 21 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 21 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 27 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 15 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 27 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 11 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 26 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 9 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 23 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 13 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 13 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 25 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 6 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 20 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 17 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 2 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 13 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 13 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 24 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 5 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 22 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 21 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 9 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 17 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 20 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 8 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 28 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 23 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 4 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 27 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 6 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 14 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 22 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 1 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 3 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 14 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 24 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 26 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 7 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 21 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Normal | 10 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Normal | 20 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Below | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Below | 10 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Normal | 23 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Normal | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Normal | 21 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Normal | 28 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | AST | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | BAS | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Below | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CAL | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | CREA | Normal | 26 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | EOS | Above | 3 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Normal | 24 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | FIBR | Above | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Below | 18 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Normal | 10 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HGB | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Below | 18 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | ALT | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | HCT | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LDH | Above | 2 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | LYM | Normal | 18 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | MON | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Below | 5 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Normal | 23 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | NEU | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Below | 8 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PLAT | Normal | 20 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PT | Normal | 27 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Below | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Normal | 25 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | PTT | Above | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Below | 24 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | RBC | Above | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Unknown | 0 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Below | 4 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | TP | Normal | 24 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Unknown | 1 Participants |
| Placebo 1D Group | Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges | WBC | Below | 7 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Any time during the study up to Day 29 after the last vaccination
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Serious Adverse Events (SAEs) | 3 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Serious Adverse Events (SAEs) | 5 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
| Placebo 1D Group | Number of Subjects With Serious Adverse Events (SAEs) | 1 Participants |
| Placebo Group | Number of Subjects With Serious Adverse Events (SAEs) | 2 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (from Day 0 up to Month 15)
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Serious Adverse Events (SAEs) | 6 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Serious Adverse Events (SAEs) | 9 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Serious Adverse Events (SAEs) | 10 Participants |
| Placebo 1D Group | Number of Subjects With Serious Adverse Events (SAEs) | 8 Participants |
Secondary
Anti-gE Geometric Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3 and 15
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK 1437173A F1 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 0 | 531.2 mIU/mL |
| GSK 1437173A F1 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 3 | 13412.9 mIU/mL |
| GSK 1437173A F1 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 1 | 1489.7 mIU/mL |
| GSK 1437173A F1 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 15 | 8052.7 mIU/mL |
| GSK 1437173A F1 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 2 | 11963.0 mIU/mL |
| GSK 1437173A F2 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 15 | 9165.5 mIU/mL |
| GSK 1437173A F2 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 3 | 13385.4 mIU/mL |
| GSK 1437173A F2 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 0 | 536.2 mIU/mL |
| GSK 1437173A F2 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 1 | 1288.1 mIU/mL |
| GSK 1437173A F2 Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 2 | 11628.8 mIU/mL |
| GSK 1437173A 2D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 0 | 448.0 mIU/mL |
| GSK 1437173A 2D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 1 | 376.1 mIU/mL |
| GSK 1437173A 2D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 3 | 972.6 mIU/mL |
| GSK 1437173A 2D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 2 | 1047.8 mIU/mL |
| GSK 1437173A 2D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 15 | 2968.0 mIU/mL |
| Placebo 1D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 0 | 659.9 mIU/mL |
| Placebo 1D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 2 | 520.2 mIU/mL |
| Placebo 1D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 1 | 619.3 mIU/mL |
| Placebo 1D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 15 | 362.3 mIU/mL |
| Placebo 1D Group | Anti-gE Geometric Mean Antibody Concentrations | At Month 3 | 585.2 mIU/mL |
Secondary
Anti-gE Mean Antibody Concentrations
Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3 and 15
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Anti-gE Mean Antibody Concentrations | At Month 3 | 88592.39 mIU/mL | Standard Deviation 133279.24 |
| GSK 1437173A F1 Group | Anti-gE Mean Antibody Concentrations | At Month 1 | 4435.62 mIU/mL | Standard Deviation 7776.94 |
| GSK 1437173A F1 Group | Anti-gE Mean Antibody Concentrations | At Month 15 | 42128.75 mIU/mL | Standard Deviation 66869.22 |
| GSK 1437173A F1 Group | Anti-gE Mean Antibody Concentrations | At Month 2 | 76302.68 mIU/mL | Standard Deviation 118526.31 |
| GSK 1437173A F1 Group | Anti-gE Mean Antibody Concentrations | At Month 0 | 683.78 mIU/mL | Standard Deviation 501.88 |
| GSK 1437173A F2 Group | Anti-gE Mean Antibody Concentrations | At Month 2 | 47344.49 mIU/mL | Standard Deviation 78643.1 |
| GSK 1437173A F2 Group | Anti-gE Mean Antibody Concentrations | At Month 3 | 62174.90 mIU/mL | Standard Deviation 94796.54 |
| GSK 1437173A F2 Group | Anti-gE Mean Antibody Concentrations | At Month 15 | 30938.91 mIU/mL | Standard Deviation 45130.79 |
| GSK 1437173A F2 Group | Anti-gE Mean Antibody Concentrations | At Month 1 | 3812.19 mIU/mL | Standard Deviation 7197.49 |
| GSK 1437173A F2 Group | Anti-gE Mean Antibody Concentrations | At Month 0 | 1366.94 mIU/mL | Standard Deviation 2510.9 |
| GSK 1437173A 2D Group | Anti-gE Mean Antibody Concentrations | At Month 2 | 2951.78 mIU/mL | Standard Deviation 4785.22 |
| GSK 1437173A 2D Group | Anti-gE Mean Antibody Concentrations | At Month 0 | 763.58 mIU/mL | Standard Deviation 818.71 |
| GSK 1437173A 2D Group | Anti-gE Mean Antibody Concentrations | At Month 1 | 675.39 mIU/mL | Standard Deviation 776.37 |
| GSK 1437173A 2D Group | Anti-gE Mean Antibody Concentrations | At Month 3 | 2739.11 mIU/mL | Standard Deviation 4458.45 |
| GSK 1437173A 2D Group | Anti-gE Mean Antibody Concentrations | At Month 15 | 16564.63 mIU/mL | Standard Deviation 30523.28 |
| Placebo 1D Group | Anti-gE Mean Antibody Concentrations | At Month 3 | 8908.62 mIU/mL | Standard Deviation 42086.07 |
| Placebo 1D Group | Anti-gE Mean Antibody Concentrations | At Month 1 | 1016.00 mIU/mL | Standard Deviation 1159.33 |
| Placebo 1D Group | Anti-gE Mean Antibody Concentrations | At Month 0 | 1025.07 mIU/mL | Standard Deviation 1177.35 |
| Placebo 1D Group | Anti-gE Mean Antibody Concentrations | At Month 2 | 927.04 mIU/mL | Standard Deviation 1221.66 |
| Placebo 1D Group | Anti-gE Mean Antibody Concentrations | At Month 15 | 1091.74 mIU/mL | Standard Deviation 1585.07 |
Secondary
Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
Time frame: At Months 0, 1, 2, 3, 4 and 15
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 0 | 356.11 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 519.79 |
| GSK 1437173A F1 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 1 | 636.10 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 886.14 |
| GSK 1437173A F1 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 2 | 3818.03 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 3773.74 |
| GSK 1437173A F1 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 3 | 3488.70 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 4130.59 |
| GSK 1437173A F1 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 4 | 5359.40 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 6486.9 |
| GSK 1437173A F1 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 15 | 3104.65 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 3543.66 |
| GSK 1437173A F2 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 15 | 3298.68 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 4326.74 |
| GSK 1437173A F2 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 3 | 3628.20 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 6682.51 |
| GSK 1437173A F2 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 0 | 449.31 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 637.09 |
| GSK 1437173A F2 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 2 | 4466.98 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 7100.05 |
| GSK 1437173A F2 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 1 | 1205.59 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 2680.05 |
| GSK 1437173A F2 Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 4 | 4243.82 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 6216.73 |
| GSK 1437173A 2D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 1 | 303.70 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 383.32 |
| GSK 1437173A 2D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 2 | 928.35 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 1773.8 |
| GSK 1437173A 2D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 3 | 887.86 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 1244.78 |
| GSK 1437173A 2D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 15 | 2669.66 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 3121.01 |
| GSK 1437173A 2D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 4 | 4481.70 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 6761.94 |
| GSK 1437173A 2D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 0 | 343.90 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 381.2 |
| Placebo 1D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 4 | 279.35 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 246.06 |
| Placebo 1D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 15 | 320.39 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 337.72 |
| Placebo 1D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 1 | 486.97 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 652.18 |
| Placebo 1D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 3 | 511.33 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 909.03 |
| Placebo 1D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 0 | 273.91 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 280.07 |
| Placebo 1D Group | Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens | At Month 2 | 249.91 VZV specific CD4+ T-cells/million Tcells | Standard Deviation 243.82 |
Secondary
Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines
The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).
Time frame: At Months 0, 1, 2, 3 and 15
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK 1437173A F1 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 3 | 7111.22 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 7755.09 |
| GSK 1437173A F1 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 1 | 856.69 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 1551.94 |
| GSK 1437173A F1 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 15 | 6865.36 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 6557.75 |
| GSK 1437173A F1 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 2 | 8830.03 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 9745.11 |
| GSK 1437173A F1 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 0 | 116.53 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 180.53 |
| GSK 1437173A F2 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 2 | 9128.95 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 12539.86 |
| GSK 1437173A F2 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 3 | 8415.89 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 12235.84 |
| GSK 1437173A F2 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 15 | 5900.24 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 7728.98 |
| GSK 1437173A F2 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 1 | 1376.95 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 3358.49 |
| GSK 1437173A F2 Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 0 | 145.97 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 217.01 |
| GSK 1437173A 2D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 2 | 1528.60 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 3204.39 |
| GSK 1437173A 2D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 0 | 83.15 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 90.39 |
| GSK 1437173A 2D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 1 | 91.84 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 118.22 |
| GSK 1437173A 2D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 3 | 827.83 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 1508.97 |
| GSK 1437173A 2D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 15 | 3859.68 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 4771.08 |
| Placebo 1D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 3 | 158.13 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 180.84 |
| Placebo 1D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 1 | 133.85 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 204.9 |
| Placebo 1D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 0 | 97.48 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 148.32 |
| Placebo 1D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 2 | 124.53 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 160.24 |
| Placebo 1D Group | Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines | At Month 15 | 71.03 gE-specific CD4+ T-cells/million T-cells | Standard Deviation 80.76 |
Secondary
Number of Subjects With Confirmed Herpes Zoster (HZ) Cases
A suspected case of HZ could be confirmed by PCR and/or by clinical review of the GSK physician responsible for the study. Rash lesion samples collected from subjects clinically diagnosed as having a suspected case of HZ were tested by by polymerase chain reaction (PCR) using standardized and validated procedures for the laboratory diagnosis of HZ. If the PCR specimen was inadequate or was missing, suspected HZ cases were to be classified as 'a confirmed case of HZ' or 'not a case of HZ' based on the determination by the GSK responsible physician of the study.
Time frame: During the entire study period (from Day 0 to Month 15)
Population: he analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK 1437173A F1 Group | Number of Subjects With Confirmed Herpes Zoster (HZ) Cases | 0 Participants |
| GSK 1437173A F2 Group | Number of Subjects With Confirmed Herpes Zoster (HZ) Cases | 2 Participants |
| GSK 1437173A 2D Group | Number of Subjects With Confirmed Herpes Zoster (HZ) Cases | 0 Participants |
| Placebo 1D Group | Number of Subjects With Confirmed Herpes Zoster (HZ) Cases | 2 Participants |
Secondary
Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations
Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3, 4 and 15
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK 1437173A F1 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 0 | 570.1 mIU/mL |
| GSK 1437173A F1 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 1 | 922.2 mIU/mL |
| GSK 1437173A F1 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 2 | 4268.5 mIU/mL |
| GSK 1437173A F1 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 3 | 3940.7 mIU/mL |
| GSK 1437173A F1 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 4 | 8484.1 mIU/mL |
| GSK 1437173A F1 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 15 | 1946.5 mIU/mL |
| GSK 1437173A F2 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 15 | 2598.2 mIU/mL |
| GSK 1437173A F2 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 3 | 4598.3 mIU/mL |
| GSK 1437173A F2 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 0 | 755.1 mIU/mL |
| GSK 1437173A F2 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 2 | 4541.3 mIU/mL |
| GSK 1437173A F2 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 1 | 1017.3 mIU/mL |
| GSK 1437173A F2 Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 4 | 6223.4 mIU/mL |
| GSK 1437173A 2D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 1 | 562.4 mIU/mL |
| GSK 1437173A 2D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 2 | 702.4 mIU/mL |
| GSK 1437173A 2D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 3 | 558.2 mIU/mL |
| GSK 1437173A 2D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 15 | 930.3 mIU/mL |
| GSK 1437173A 2D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 4 | 3196.6 mIU/mL |
| GSK 1437173A 2D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 0 | 639.9 mIU/mL |
| Placebo 1D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 4 | 351.9 mIU/mL |
| Placebo 1D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 15 | 339.4 mIU/mL |
| Placebo 1D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 1 | 729.4 mIU/mL |
| Placebo 1D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 3 | 632.7 mIU/mL |
| Placebo 1D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 0 | 659.2 mIU/mL |
| Placebo 1D Group | Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations | At Month 2 | 523.5 mIU/mL |
Secondary
VZV-specific Mean Antibody Concentrations
Concentrations are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).
Time frame: At Months 0, 1, 2, 3, 4 and 15
Population: The analyses were performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented. Only subjects with results available were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GSK 1437173A F1 Group | VZV-specific Mean Antibody Concentrations | At Month 0 | 968.22 mIU/mL | Standard Deviation 1466.46 |
| GSK 1437173A F1 Group | VZV-specific Mean Antibody Concentrations | At Month 3 | 13342.90 mIU/mL | Standard Deviation 19278.57 |
| GSK 1437173A F1 Group | VZV-specific Mean Antibody Concentrations | At Month 1 | 1881.91 mIU/mL | Standard Deviation 2742.85 |
| GSK 1437173A F1 Group | VZV-specific Mean Antibody Concentrations | At Month 15 | 4694.74 mIU/mL | Standard Deviation 5945.23 |
| GSK 1437173A F1 Group | VZV-specific Mean Antibody Concentrations | At Month 2 | 15155.95 mIU/mL | Standard Deviation 22198.03 |
| GSK 1437173A F1 Group | VZV-specific Mean Antibody Concentrations | At Month 4 | 23858.74 mIU/mL | Standard Deviation 31173.45 |
| GSK 1437173A F2 Group | VZV-specific Mean Antibody Concentrations | At Month 2 | 10934.78 mIU/mL | Standard Deviation 13735.35 |
| GSK 1437173A F2 Group | VZV-specific Mean Antibody Concentrations | At Month 4 | 16752.32 mIU/mL | Standard Deviation 17738.95 |
| GSK 1437173A F2 Group | VZV-specific Mean Antibody Concentrations | At Month 3 | 12602.99 mIU/mL | Standard Deviation 18030.89 |
| GSK 1437173A F2 Group | VZV-specific Mean Antibody Concentrations | At Month 15 | 5482.75 mIU/mL | Standard Deviation 5769.88 |
| GSK 1437173A F2 Group | VZV-specific Mean Antibody Concentrations | At Month 1 | 1957.16 mIU/mL | Standard Deviation 2438 |
| GSK 1437173A F2 Group | VZV-specific Mean Antibody Concentrations | At Month 0 | 1340.29 mIU/mL | Standard Deviation 1685.09 |
| GSK 1437173A 2D Group | VZV-specific Mean Antibody Concentrations | At Month 2 | 1506.49 mIU/mL | Standard Deviation 2120.19 |
| GSK 1437173A 2D Group | VZV-specific Mean Antibody Concentrations | At Month 0 | 1304.22 mIU/mL | Standard Deviation 1866.32 |
| GSK 1437173A 2D Group | VZV-specific Mean Antibody Concentrations | At Month 3 | 1227.40 mIU/mL | Standard Deviation 1794.62 |
| GSK 1437173A 2D Group | VZV-specific Mean Antibody Concentrations | At Month 1 | 1089.57 mIU/mL | Standard Deviation 1586.68 |
| GSK 1437173A 2D Group | VZV-specific Mean Antibody Concentrations | At Month 4 | 10744.24 mIU/mL | Standard Deviation 17397.97 |
| GSK 1437173A 2D Group | VZV-specific Mean Antibody Concentrations | At Month 15 | 2956.21 mIU/mL | Standard Deviation 4515.53 |
| Placebo 1D Group | VZV-specific Mean Antibody Concentrations | At Month 15 | 835.21 mIU/mL | Standard Deviation 947.65 |
| Placebo 1D Group | VZV-specific Mean Antibody Concentrations | At Month 4 | 753.59 mIU/mL | Standard Deviation 1155.17 |
| Placebo 1D Group | VZV-specific Mean Antibody Concentrations | At Month 1 | 1158.99 mIU/mL | Standard Deviation 1407.26 |
| Placebo 1D Group | VZV-specific Mean Antibody Concentrations | At Month 0 | 843.07 mIU/mL | Standard Deviation 616.78 |
| Placebo 1D Group | VZV-specific Mean Antibody Concentrations | At Month 3 | 2902.89 mIU/mL | Standard Deviation 10461.29 |
| Placebo 1D Group | VZV-specific Mean Antibody Concentrations | At Month 2 | 911.09 mIU/mL | Standard Deviation 1211.24 |